Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Rating) have received an average rating of "Buy" from the thirteen research firms that are presently covering the company, MarketBeat Ratings reports. Twelve analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have covered the stock in the last year is $27.08.
A number of equities analysts recently weighed in on TSHA shares. Guggenheim lowered their price objective on shares of Taysha Gene Therapies to $22.00 and set a "na" rating on the stock in a research report on Tuesday, May 17th. The Goldman Sachs Group reduced their target price on Taysha Gene Therapies from $27.00 to $16.00 and set a "buy" rating for the company in a report on Tuesday, May 24th. Wedbush cut their price target on Taysha Gene Therapies from $9.00 to $5.00 and set an "outperform" rating for the company in a research note on Friday. Needham & Company LLC cut their target price on shares of Taysha Gene Therapies to $20.00 and set a "buy" rating for the company in a research note on Tuesday, May 17th. Finally, Chardan Capital cut their target price on shares of Taysha Gene Therapies from $34.00 to $32.00 and set a "buy" rating for the company in a research note on Friday.
Get Taysha Gene Therapies alerts:Taysha Gene Therapies Stock Up 5.9 %
Shares of TSHA opened at $4.34 on Thursday. The stock has a market capitalization of $175.97 million, a PE ratio of -0.90 and a beta of 0.99. Taysha Gene Therapies has a 1 year low of $2.33 and a 1 year high of $21.90. The company has a debt-to-equity ratio of 1.15, a quick ratio of 1.79 and a current ratio of 1.79. The company's 50-day simple moving average is $3.97 and its 200-day simple moving average is $4.88.
Taysha Gene Therapies (NASDAQ:TSHA – Get Rating) last announced its earnings results on Monday, May 16th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.04) by ($0.27). During the same period last year, the firm posted ($0.87) EPS. Analysts forecast that Taysha Gene Therapies will post -4.1 earnings per share for the current fiscal year.Insider Activity at Taysha Gene Therapies
In related news, CMO Suyash Prasad sold 23,923 shares of the firm's stock in a transaction dated Friday, July 1st. The stock was sold at an average price of $3.53, for a total transaction of $84,448.19. Following the completion of the transaction, the chief marketing officer now owns 543,450 shares of the company's stock, valued at $1,918,378.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 40,152 shares of company stock valued at $145,109 over the last 90 days. 42.40% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Taysha Gene Therapies
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Occudo Quantitative Strategies LP grew its holdings in Taysha Gene Therapies by 17.9% in the 2nd quarter. Occudo Quantitative Strategies LP now owns 31,030 shares of the company's stock valued at $115,000 after buying an additional 4,702 shares during the last quarter. AQR Capital Management LLC bought a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth approximately $38,000. Nantahala Capital Management LLC lifted its position in shares of Taysha Gene Therapies by 23.2% in the 2nd quarter. Nantahala Capital Management LLC now owns 1,643,438 shares of the company's stock worth $6,114,000 after acquiring an additional 309,491 shares during the period. Laurion Capital Management LP bought a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth approximately $1,646,000. Finally, Millennium Management LLC bought a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth approximately $804,000. 46.05% of the stock is owned by hedge funds and other institutional investors.
Taysha Gene Therapies Company Profile
(Get Rating)
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.
Featured Articles
- Get a free copy of the StockNews.com research report on Taysha Gene Therapies (TSHA)
- 3 Blowout Earnings Reports That Could Mark Turning Points
- 3 Stocks Set to Lead the Nasdaq Bull Market
- Skyworks Solutions Is Worth A Look At These Prices
- Will CrowdStrike Extend Its Streak Of Topping Earnings Views?
- MarketBeat Podcast: ESG – Profitably Invest Your Values
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.